Global Longlife

Why is Global Longlife Hospital and Research Ltd falling/rising?

As of 01-Sep, the stock price of Global Longlife Hospital and Research Ltd is rising to 11.70, up 4.46%. This increase is driven by strong relative performance, consecutive gains, heightened investor interest, and positive momentum indicators.

As of 01-Sep, the stock price of Global Longlife Hospital and Research Ltd is rising, currently at 11.70, reflecting an increase of 0.5 or 4.46%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 5.59% today, indicating strong relative performance. Additionally, it has experienced consecutive gains over the last three days, accumulating a total return of 11.68% during this period. <BR><BR>Investor participation has also increased, as evidenced by a significant rise in delivery volume, which was 41,000 on August 31, marking a 153.09% increase compared to the 5-day average. This suggests heightened interest and confidence from investors. Furthermore, the stock's current price is above its 5-day, 20-day, and 50-day moving averages, which typically signals positive momentum. <BR><BR>Overall, these factors contribute to the stock's rising price, despite its longer-term performance showing declines over the year and beyond.

Who are in the management team of Global Longlife?

The management team of Global Longlife includes Sureshkumar Babulal Jani (Chairman/Executive Director), Dhruv Sureshkumar Jani (Managing Director), Sucheta Dhruvkumar Jani (Non-Executive & Non-Independent Director), Manasvi Manu Thapar (Independent Non-Executive Director), and Sandeep M Shah (Independent Non-Executive Director).

The management team of Global Longlife includes the following members:<BR><BR>1. **Sureshkumar Babulal Jani** - Chairman / Executive Director<BR>2. **Dhruv Sureshkumar Jani** - Managing Director<BR>3. **Sucheta Dhruvkumar Jani** - Non-Executive & Non-Independent Director<BR>4. **Manasvi Manu Thapar** - Independent Non-Executive Director<BR>5. **Sandeep M Shah** - Independent Non-Executive Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

What does Global Longlife do?

Global Longlife Hospital and Research Ltd is a micro-cap company in the hospital industry, incorporated in 2012 and converted to a public company in 2021, with net sales of 12 Cr and a net profit of 1 Cr reported for March 2023. The company has a market cap of INR 11 Cr and key financial metrics indicating negative returns and no dividends.

Overview:<BR>Global Longlife Hospital and Research Ltd operates in the hospital industry and is classified as a micro-cap company.<BR><BR>History:<BR>The company was originally incorporated as "Global Longlife Hospital and Research Private Limited" in 2012 and later converted to a public limited company in 2021. The latest quarterly results reported net sales and net profit for March 2023.<BR><BR>Financial Snapshot:<BR>Net Sales: 12 Cr (Quarterly Results - Mar 2023) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2023) <BR>Market Cap: INR 11 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.72 <BR>Return on Equity: -7.24% <BR>Price to Book: 0.48 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Global Longlife?

Global Longlife's peers include Fortis Malar, Shanmuga Hospital, Soni Medicare, KK Shah Hospital, Broach Lifecare, Nidan Laboratories, Docmode Health, Aatmaj Health, and Sangani Hospital. Global Longlife has average management risk, below average growth, and the lowest 1-year return at -55.47% among its peers.

Peers: The peers of Global Longlife are Fortis Malar, Shanmuga Hos., Soni Medicare, KK Shah Hospital, Broach Lifecare, Nidan Laborator., Docmode Health, Aatmaj Health, and Sangani Hospital.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shanmuga Hos. and Aatmaj Health, while Average management risk is found at Global Longlife. Below Average management risk is noted at Fortis Malar, Soni Medicare, KK Shah Hospital, Broach Lifecare, Nidan Laborator., Docmode Health, and Sangani Hospital. Growth is Excellent at Sangani Hospital, Average at Global Longlife and Aatmaj Health, and Below Average at Fortis Malar, Shanmuga Hos., Soni Medicare, KK Shah Hospital, Broach Lifecare, Nidan Laborator., Docmode Health. Capital Structure is Excellent at Shanmuga Hos., Good at KK Shah Hospital, Broach Lifecare, and Aatmaj Health, and Below Average at Fortis Malar, Soni Medicare, Global Longlife, Nidan Laborator., Docmode Health, and Sangani Hospital.<BR><BR>Return Snapshot: The peer with the highest 1-year return is KK Shah Hospital at 0.00%, while the peer with the lowest is Global Longlife at -55.47%. Global Longlife's 1-year return is significantly lower than that of all its peers. Additionally, peers with negative six-month returns include Fortis Malar and Global Longlife.

How big is Global Longlife?

As of 31st August, Global Longlife Hospital and Research Ltd has a market capitalization of 11.00 Cr, with net sales of 23.50 Cr and a net profit of 1.83 Cr over the latest four quarters. Shareholder's funds are recorded at 23.75 Cr, and total assets are valued at 21.41 Cr as of March 2026.

As of 31st August, Global Longlife Hospital and Research Ltd has a market capitalization of 11.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported a sum of Net Sales amounting to 23.50 Cr. The sum of Net Profit for the same period was 1.83 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, where Shareholder's Funds are recorded at 23.75 Cr and Total Assets are valued at 21.41 Cr.

Which are the latest news on Global Longlife?

How has been the historical performance of Global Longlife?

Global Longlife has experienced a significant decline in financial performance, with net sales dropping from 32.82 Cr in Mar'22 to 0.58 Cr in Mar'25, and operating profit turning negative at -4.16 Cr. Total assets and liabilities have also decreased, while cash flow from operations remains negative, indicating ongoing operational challenges.

Answer:<BR>The historical performance of Global Longlife shows a significant decline in net sales and operating income over the past few years, with net sales dropping from 32.82 Cr in Mar'22 to just 0.58 Cr in Mar'25. Total operating income followed a similar trend, decreasing from 32.82 Cr in Mar'22 to 0.58 Cr in Mar'25. The company experienced a negative operating profit (PBDIT) in Mar'25 at -4.16 Cr, contrasting with a positive operating profit of 8.03 Cr in Mar'22. Profit before tax also saw a decline, moving from 5.71 Cr in Mar'22 to 0.10 Cr in Mar'25, while profit after tax improved slightly to 0.20 Cr in Mar'25 from a loss of 2.19 Cr in Mar'24. The company's total assets decreased from 73.79 Cr in Mar'23 to 24.50 Cr in Mar'25, and total liabilities also fell from 39.51 Cr in Mar'24 to 24.50 Cr in Mar'25. Cash flow from operating activities remained negative, indicating ongoing challenges in generating cash from core operations.<BR><BR>Breakdown:<BR>Global Longlife's financial trajectory reveals a concerning decline in key metrics. Net sales have plummeted from 32.82 Cr in Mar'22 to a mere 0.58 Cr in Mar'25, reflecting a drastic reduction in operational capacity. This decline is mirrored in total operating income, which fell from 32.82 Cr to 0.58 Cr over the same period. The operating profit (PBDIT) transitioned from a healthy 8.03 Cr in Mar'22 to a negative 4.16 Cr in Mar'25, indicating significant operational challenges. Profit before tax also deteriorated, moving from 5.71 Cr to 0.10 Cr, while profit after tax showed a slight recovery to 0.20 Cr in Mar'25 from a loss in the previous year. The company's total assets and liabilities have both decreased, with total assets dropping from 73.79 Cr to 24.50 Cr and total liabilities from 39.51 Cr to 24.50 Cr, suggesting a shrinking balance sheet. Cash flow from operating activities has remained negative, highlighting ongoing difficulties in generating cash from operations.

Who are the top shareholders of the Global Longlife?

The top shareholders of Global Longlife are Dhruv Sureshkumar Jani with 37.13%, followed by public shareholder Yogeshkumar Rasiklal Sanghavi at 3.67%, and individual investors collectively holding 33.71%. There are no mutual funds or foreign institutional investors in the company.

The top shareholders of Global Longlife include Dhruv Sureshkumar Jani, who is the promoter with the highest holding at 37.13%. The highest public shareholder is Yogeshkumar Rasiklal Sanghavi, holding 3.67%. Additionally, individual investors collectively hold 33.71% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

Is Global Longlife overvalued or undervalued?

As of February 1, 2024, Global Longlife is considered risky and overvalued, with a PE ratio of 31.43 and negative EV to EBITDA, raising concerns about its profitability and financial health compared to peers like Max Healthcare and Apollo Hospitals.

As of 1 February 2024, the valuation grade for Global Longlife has moved from very attractive to risky. The company is currently assessed as overvalued. Key ratios include a PE ratio of 31.43, an EV to EBITDA of -10.52, and a PEG ratio of 0.29, indicating potential concerns regarding profitability and growth expectations.<BR><BR>In comparison to its peers, Global Longlife's PE ratio is significantly lower than that of Max Healthcare Institute Ltd., which stands at 100.29, and Apollo Hospitals Enterprise Ltd. at 69.03, both of which are categorized as very expensive. This suggests that while Global Longlife may appear less expensive on a PE basis, its negative EV to EBITDA and low ROE of 0.84% raise red flags about its financial health and operational efficiency. Additionally, the company's stock has underperformed the Sensex over the past year, further reinforcing the notion of overvaluation.

What is the technical trend for Global Longlife?

As of May 15, 2025, Global Longlife's trend is mildly bearish, influenced by daily moving averages and mixed signals from MACD and Bollinger Bands, suggesting a cautious outlook.

As of 15 May 2025, the technical trend for Global Longlife has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend. The weekly MACD shows a mildly bullish signal, but this is countered by the monthly MACD being mildly bearish. Additionally, Bollinger Bands on a monthly basis are bearish, while the weekly Bollinger Bands are mildly bullish. The KST is bullish on a weekly basis, yet the Dow Theory indicates no trend in both weekly and monthly time frames. Overall, the mixed signals suggest a cautious outlook with a slight bearish bias.

When is the next results date for Global Longlife?

No Upcoming Board Meetings

Has Global Longlife declared dividend?

No Dividend History Available